financetom
Business
financetom
/
Business
/
Edison International Q3 Core Earnings, Revenue Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Edison International Q3 Core Earnings, Revenue Rise
Nov 3, 2024 2:27 PM

04:46 PM EDT, 10/29/2024 (MT Newswires) -- Edison International ( EIX ) reported Q3 core earnings late Tuesday of $1.51 per share, up from $1.38 per share a year earlier.

Analysts polled by Capital IQ expected $1.39.

Operating revenue for the quarter ended Sept. 30 was $5.2 billion, up from $4.7 billion a year earlier.

Analysts surveyed by Capital IQ expected $5.01 billion.

The company said it now expects full-year 2024 core EPS of $4.80 to $5.00 against $4.75 to $5.05 previously. Analysts surveyed by Capital IQ expect $4.94.

Price: 83.09, Change: -0.05, Percent Change: -0.06

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Teva Pharmaceuticals International Enters Collaboration to Commercialize Eye Disease Treatment
Teva Pharmaceuticals International Enters Collaboration to Commercialize Eye Disease Treatment
Jan 13, 2025
04:32 AM EST, 01/13/2025 (MT Newswires) -- Teva Pharmaceutical Industries' ( TEVA ) Teva Pharmaceuticals International subsidiary said Monday it has entered into a collaboration with Klinge Biopharma and Formycon for the semi-exclusive commercialization of FYB203, Formycon's biosimilar candidate to Eylea, in Israel and Europe, excluding Italy. Financial terms were not disclosed. Klinge has licensed the exclusive global commercialization rights...
Caribou Biosciences Starts Phase 1 Trial for Lupus Drug Candidate
Caribou Biosciences Starts Phase 1 Trial for Lupus Drug Candidate
Jan 13, 2025
04:47 AM EST, 01/13/2025 (MT Newswires) -- Caribou Biosciences ( CRBU ) said Sunday it initiated the phase 1 trial evaluating its experimental therapy, CB-010, in patients with lupus nephritis and extrarenal lupus. Additionally, the company said it expects to report data from a study of CB-010 to treat certain large B cell lymphoma patients in the first half of...
BP Azerbaijan says working to resume work of Shah Deniz platform as soon as possible
BP Azerbaijan says working to resume work of Shah Deniz platform as soon as possible
Jan 13, 2025
BAKU, Jan 13 (Reuters) - BP is working to resolve technical problems at the Shah Deniz Alfa (SDA) platform and hopes to resume normal operations as soon as possible, the company told Reuters on Monday. BP suspended work of the platform on Friday after detecting a technical issue at the subsea gas condensate export line between the platform and the...
Illumina Starts Pilot Program With Partners to Generate Proteomics Data
Illumina Starts Pilot Program With Partners to Generate Proteomics Data
Jan 13, 2025
04:39 AM EST, 01/13/2025 (MT Newswires) -- Illumina ( ILMN ) said Monday it started a pilot proteomics program to analyze 50,000 UK Biobank samples in partnership with deCODE Genetics, Standard BioTools, Tecan, GSK (GSK), Johnson & Johnson ( JNJ ) , and Novartis ( NVS ) . Under the collaboration, deCODE Genetics will process the samples from the UK...
Copyright 2023-2026 - www.financetom.com All Rights Reserved